Search the Newsroom
Filter By
News Type
Showing 1 - 10 of 25 results
New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response
A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.
Abu Dhabi Health Services Company (SEHA) and Children’s Hospital of Philadelphia (CHOP) align to boost medical research and education in the UAE
Abu Dhabi Health Services Company (SEHA), the UAE’s largest healthcare network, has signed a Memorandum of Understanding (MoU) with Children’s Hospital of Philadelphia (CHOP) to facilitate enhanced international collaboration and further propel the quality of medical education, research, and patient experience within the UAE.
First Approved CAR T-Cell Therapy Shows Continued Benefits Five Years Later
New data on show CAR T-cell therapy leads to durable remission and long-term survival in children and young adults with relapsed or refractory B-ALL.
CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.
CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.
CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).
CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion
A new study in Nature has documented the longest persistence of CAR T cell therapy to date.
Aberrant Splicing of CD22 in Acute Lymphoblastic Leukemia Underlies Resistance to Immunotherapy
Aberrant splicing leads to downregulation of CD22 in pediatric B-ALL, rendering malignant cells resistant to the effects of CD22-directed immunotherapies.
CHOP Researchers Develop Humanized CAR T-Cell Therapy that Shows Potential for Patients with Relapsed B-ALL
The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.
Researchers Uncover How MN1 Overexpression Causes AML
CHOP researchers have found that MN1 overexpression leads to stabilization of the BAF complex, which leads to overproduction of progenitor and stem cells.